Zoomed Image
  • Combivent Nebulizer Liquid 2.5ml 20's

Combivent Nebulizer Liquid 2.5ml 20's

Qualitative and quantitative composition: Each 2.5 ml single dose unit contains 500 micrograms ipratropium bromide (as 520 micrograms ipratropium bromide monohydrate) and 3 mg salbutamol sulfate (corresponds to 2.5mg salbutamol base). Therapeutic indications: The management of bronchospasm in patients suffering from chronic obstructive pulmonary disease who require regular treatment with both ipratropium and salbutamol. COMBIVENT UDVs are intended for inhalation only and may be administered from a suitable nebuliser or an intermittent positive pressure ventilator. The single dose units must not be taken orally or administered parenterally. Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician. The treatment with the nebuliser solution in UDVs should always be started with the lowest recommended dose (1 UDV). In very severe cases two unit dose vials may be required for symptom relief. Administration should be stopped when sufficient symptom relief is achieved.
How to use
he recommended dose is: Adults (including elderly patients and children over 12 years): 1 single dose unit three or four times daily. Children under 12 years: There is no experience of the use of COMBIVENT UDVs in children under 12 years. Administration: Please refer to the patient information leaflet for instructions for use with a nebuliser. Since the single dose units contain no preservatives, it is important that the contents are used immediately after opening and that a fresh vial is used for each administration to avoid microbial contamination. Partly used, open or damaged single dose units should be discarded. It is strongly recommended not to mix COMBIVENT UDVs with other drugs in the same nebuliser.
Contraindications: COMBIVENT UDVs are contraindicated in patients with hypertrophic obstructive cardio-myopathy or tachyarrhythmia. COMBIVENT UDVs are also contraindicated in patients with a history of hypersensitivity to ipratropium bromide, salbutamol sulfate or to atropine or its derivatives.